NASDAQ: SBTX

Silverback Therapeutics, Inc.

Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Silverback Therapeutics, Inc. (NASDAQ: SBTX): (1) pursuant and/or traceable to the registration statement and prospectus issued in connection with the Company’s December 3, 2020 initial public offering (“IPO”); and/or (2) between December 3, 2020 and September 10, 2021, inclusive (the “Class Period”). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than January 4, 2022.

If you purchased Silverback securities and would like to join the action, please click “Join This Class Action.”

Class Period:Pursuant and/or traceable to the Company’s December 3, 2020 initial public offering (“IPO”) and/or between December 3, 2020 through September 10, 2021
If you purchased Silverback securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

Details of the case:

According to the lawsuit, the IPO documents featured and defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that:

  • Silverback’s lead product candidate SBT6050 (a TLR8 agonist linker-payload conjugated to a HER2-directed monoclonal antibody that targets tumors, such as breast, gastric, and non-small cell lung cancers) was less effective than the Company had represented to investors;
  • accordingly, the Company had overstated SBT6050’s commercial and/or clinical prospects; and
  • as a result, the IPO documents and defendants’ public statements throughout the Class Period were materially false and/or misleading and failed to state information required to be stated therein.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Follow us on:
Company Name: Silverback Therapeutics, Inc.
Stock Symbol: SBTX
Class Period: Pursuant and/or traceable to the Company’s December 3, 2020 initial public offering (“IPO”) and/or between December 3, 2020 through September 10, 2021
Court: United States District Court for the Western District of Washington

Why Rosen Law

The Rosen Law Firm has been ranked among the top 4 law firms each year since 2013 for the number of successful securities class actions on behalf of investors. In 2019 alone, our firm recovered $438 million for investors.

Investors should carefully identify and select experienced counsel with a track record of success leading securities class actions. Often other firms issue press releases about class actions yet do not have comparable experience or resources.

Institutional Shareholders Services ranked the Rosen Law Firm # 1 for the number of securities class action recoveries in 2017.

The Rosen Law Firm represents investors throughout the globe. Our mission is to prosecute securities fraud class actions and protect shareholders’ rights.

Scroll to Top